IP Library Granted Patent US 11,957,720
Granted Patent B2
US 11,957,720 · App. 17/730,891 · Granted Apr 16, 2024

Patent

Inventors: Peter McLean (Lausanne, CH); Gabriela Bergonzelli Degonda (Bussigny, CH); Stephen Michael Collins (Ontario, CA); Premysl Bercik (Ontario, CA); Elena Verdu de Bercik (Ontario, CA)
Assignee: Societe des Produits Nestle S.A.
A61K35/74A23K10/18A23L33/135A61K35/745C12N1/20A23K20/163A23L33/21A23V2002/00A23V2400/533
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,957,720
App. No.
17/730,891
Granted
Apr 16, 2024
Kind
B2
Abstract

The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum , such as Bifidobacterium longum ATCC BAA-999.

Claims (17)

1. A method for treatment of irritable bowel syndrome and anxiety in a subject in need thereof, the method comprising:

administering to the subject a composition comprising Bifidobacterium longum ATCC BAA-999 and a B vitamin,

wherein the composition is selected from the group consisting of a dietary supplement, a nutraceutical, a drink, and a medical composition.

2. The method of claim 1 , wherein the composition comprises at least one other type of food grade bacteria.

3. The method of claim 2 , wherein the at least one other type of food grade bacteria is selected from the group consisting of lactic acid bacteria and propionibacteria.

4. The method of claim 1 , wherein the composition comprises at least one prebiotic.

5. The method of claim 4 , wherein the at least one prebiotic is selected from the group consisting of oligosaccharides and dietary fibers.

6. The method of claim 1 , wherein at least 5% of Bifidobacterium longum ATCC BAA-999 cells are viable in the composition.

7. The method of claim 1 , wherein at least 80% of Bifidobacterium longum ATCC BAA-999 cells are non-replicating in the composition.

8. The method of claim 1 , wherein the composition comprises between 10 4 and 10 10 cells of Bifidobacterium longum ATCC BAA-999 per daily dose.

9. The method of claim 1 , wherein the composition comprises between 10 2 and 10 8 cells of Bifidobacterium longum ATCC BAA-999 per g dry weight of the composition.

10. The method of claim 1 , wherein the composition comprises a protein source comprising hydrolyzed whey protein.

11. The method of claim 1 , wherein the composition is in powder form having a water activity of less than 0.2.

12. The method of claim 1 , wherein the B vitamin is selected from the group consisting of Vitamin B1, Vitamin B6, Vitamin B2, niacin, Vitamin B12, folic acid, biotin, and mixtures thereof.

13. The method of claim 1 , wherein the composition comprises at least one of 1 to 2 mg Vitamin B1, 0.5 to 1.5 mg Vitamin B6, 0.5 to 2 mg Vitamin B2, 5 to 18 mg niacin, 0.5 to 2.0 μg Vitamin B12, 100 to 800 μg folic acid, or 30 to 70 μg biotin.

14. The method of claim 1 , wherein the composition further comprises at least one of a protein, a fat source, and a source of carbohydrates.

15. The method of claim 14 , wherein the composition further comprises at least one of 5 wt. % to 40 wt. % of a fat source and 40 wt. % to 80 wt. % of a source of carbohydrates.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2023
From: MCLEAN, PETER; BERGONZELLI DEGONDA, GABRIELA; COLLINS, STEPHEN MICHAEL; BERCIK, PREMYSI; DE BERCIK, ELENA VERDU
To: NESTEC S.A.
Reel/Frame 064918/0275 →
MERGER Recorded Sep 15, 2023
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 064918/0375 →
Priority Claims (1)
EP 09168590 · Aug 25, 2009 · regional
Continuity (3)
Continuation 16023503 · Jun 29, 2018
Continuation 13391343
Related Publication 20220280576A1 · Sep 8, 2022